Effects of statin therapy on atherosclerosis progression, inflammation and lipid profiles in patients with systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials.
Natanael de Paula Portilho, Eline Rozária Ferreira Barbosa, Muhammad Younas et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis pooled six randomized, placebo-controlled trials involving 668 patients with systemic lupus erythematosus (SLE) to assess statin effects on atherosclerosis markers, inflammation, lipids, and disease activity. Across a mean follow-up of 18.5 months, statins reduced LDL cholesterol by MD -35.49 mg/dL (95% CI -57.14, -13.83; p < 0.01) and also improved hs-CRP and total cholesterol. No significant differences were found in carotid intima-media thickness, coronary artery calcium score, or SLE disease activity. The authors rated the evidence low to very low certainty.
Key findings
- Statins reduced LDL cholesterol versus placebo (MD -35.49 mg/dL; 95% CI -57.14, -13.83; p < 0.01).
- hs-CRP decreased with statin therapy (MD -0.61 mg/L; 95% CI -1.12, -0.11; p = 0.017).
- Total cholesterol decreased (MD -38.85 mg/dL; 95% CI -66.74, -10.95; p < 0.01).
- No significant differences were observed in CIMT, CAC, or SLEDAI.
Why it matters
People with SLE have increased risk of premature atherosclerosis, making cardiovascular risk reduction an important concern. These pooled trial results suggest statins improve lipid and inflammatory markers in this population, but the absence of significant changes in structural atherosclerosis measures means marker improvements should not be assumed to demonstrate reduced atherosclerosis progression.
What to keep in mind
The evidence was rated low to very low certainty, and the trials had a mean follow-up of 18.5 months. The authors call for adequately powered, long-term randomized trials.